Radioactive antibody could boost stem cell transplant success in tough leukemia
NCT ID NCT07157514
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a new approach for people with relapsed or refractory acute myeloid leukemia (AML) who have active disease. Before a stem cell transplant, patients receive a radioactive antibody (131I-apamistamab) along with chemotherapy and low-dose radiation to prepare the body. The goal is to see if this combination helps patients live longer and achieve remission. The trial has two parts: first finding the best dose, then comparing it to standard care in about 306 adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 131I-apamistamab (a radioactive antibody targeting cancer cells)
- What this could lead to
- If successful, this could offer a more effective transplant preparation for people with hard-to-treat AML, potentially improving survival and remission rates.
- What could go wrong
- This is an early-to-mid-stage trial, so the benefits are not proven. The treatment involves radiation and strong chemotherapy, which carry risks like severe side effects or transplant complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?